Patents by Inventor Pascal Danglas

Pascal Danglas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING PRADER-WILLI SYNDROME
    Publication number: 20240082344
    Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 18, 2022
    Publication date: March 14, 2024
    Applicant: Ferring B.V.
    Inventors: Pascal DANGLAS, Michael REIDY, Paul KORNER, Sudarkodi ALAGARSAMY
  • Bacteriophage therapy
    Patent number: 11918613
    Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: March 5, 2024
    Assignees: FERRING B.V., INSTITUT PASTEUR
    Inventors: Pascal Danglas, Laurent Debarbieux
  • BACTERIOPHAGE THERAPY
    Publication number: 20210386805
    Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
    Type: Application
    Filed: June 21, 2021
    Publication date: December 16, 2021
    Applicants: FERRING B.V., INSTITUT PASTEUR
    Inventors: Pascal Danglas, Laurent Debarbieux
  • Bacteriophage therapy
    Patent number: 11040078
    Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: June 22, 2021
    Assignees: FERRING B.V., INSTITUT PASTEUR
    Inventors: Pascal Danglas, Laurent Debarbieux
  • METHOD OF TREATING PRADER-WILLI SYNDROME
    Publication number: 20200129584
    Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2019
    Publication date: April 30, 2020
    Applicant: FERRING B.V.
    Inventors: Pascal DANGLAS, Michael REIDY, Paul KORNER, Sudarkodi ALAGARSAMY
  • Method of treating prader-willi syndrome
    Patent number: 10441627
    Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 15, 2019
    Assignee: FERRING B.V.
    Inventors: Pascal Danglas, Michael Reidy, Paul Korner, Sudarkodi Alagarsamy
  • Method of Treating Prader-Willi Syndrome
    Publication number: 20170326200
    Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2015
    Publication date: November 16, 2017
    Inventors: Pascal Danglas, Michael Reidy, Paul Korner, Sudarkodi Alagarsamy
  • BACTERIOPHAGE THERAPY
    Publication number: 20160143965
    Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
    Type: Application
    Filed: April 30, 2014
    Publication date: May 26, 2016
    Applicants: FERRING B.V., INSTITUT PASTEUR
    Inventors: Pascal Danglas, Laurent Debarbieux